----------------------------------
COSTS AND EXPENSES:
Research and development 8,990,469 5,109,224
General and administrative 3,809,073 2,197,014
----------------------------------
Total costs and expenses 12,799,542 7,306,238
----------------------------------
OPERATING (LOSS) INCOME (12,335,250) (1,841,947)
INVESTMENT INCOME 585,048 390,093
INTEREST EXPENSE (386,161) (5,092)
----------------------------------
(LOSS) INCOME BEFORE INCOME TAXES (12,136,363) (1,456,946)
PROVISION FOR INCOME TAXES - -
----------------------------------
NET (LOSS) INCOME (12,136,363) (1,456,946)
REDEEMABLE PREFERRED STOCK ACCRETION - 286,834
----------------------------------
NET (LOSS) INCOME ATTRIBUTABLE TO
COMMON STOCKHOLDERS $(12,136,363) $(1,743,780)
==================================
COMPREHENSIVE NET (LOSS) INCOME:
NET (LOSS) INCOME $(12,136,363) $(1,456,946)
UNREALIZED GAIN (LOSS) ON AVAILABLE-
FOR-SALE INVESTMENTS (29,572) 230
----------------------------------
COMPREHENSIVE NET (LOSS) INCOME: $(12,165,935) $(1,456,716)
==================================
NET (LOSS) INCOME
'/>"/>
| SOURCE Pharmasset, Inc. Copyright©2008 PR Newswire. All rights reserved |